This guide provides a compilation of insights from legal practitioners around the world to assist in the identification and understanding of the laws and regulations that impact the drug and medical device industry.
Some states have restricted medical care for employees such as restricting abortions and gender-affirming care. In this sample policy Glowforge Inc. pays for the travel or relocation to get the healthcare the company has promised its employees. The policy was issued on April 14, 2022.
Implications of US Supreme Court's decision in Dobbs v. Jackson Women's Health Organization for employers in the United States
Many California health care providers, including hospitals and physician groups, will soon be required to sign on to California’s first-ever statewide data sharing agreement governing the exchange of health and social services information. Learn more here.
This article discusses the US Drug Enforcement Agency's (DEA) new regulation temporarily extending the “full set” of COVID-19 waivers for prescribing controlled substances via telemedicine.
Originally published by Foley & Lardner LLP on May 11, 2023.
This article focuses on the Centers for Medicare & Medicaid Services (CMS) massive rule (Final Rule)2 amending regulations for Medicare Advantage (MA or Part C), Medicare Cost Plan, the Medicare Prescription Drug Benefit (Part D) programs, and Programs of All-Inclusive Care for the Elderly (PACE).
In this multi-jurisdictional guide, explore an overview of key legal issues, rules and developments regarding pharmaceutical advertising across a range of jurisdictions.
This is a sample business development agreement, for a non-exclusive cooperative marketing relationship to promote collection services (governed by Ohio law).
This guide provided by Foley & Lardner summarizes the key elements and requirements contained in the proposed rule. In addition it explains how it differs from the special telemedicine registration rule. Finally, it describes what stakeholders can do to make their voice heard, including by submitting comments to the proposed rule, during these next 30 days.
This article discusses the U.S. Food and Drug Administration's draft guidance regarding the implementation of Decentralized Clinical Trials (DCTs) for drugs, biological products, and devices.